FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody which specifically binds to human CD19, as well as to a pharmaceutical composition containing it. Also disclosed is use of said antibody in preparing a drug for CD19 binding. Invention also relates to a method for B-cell population depletion involving using said antibody.
EFFECT: invention enables effective treatment of a patient suffering from a disease associated with a pathological increase in the number of B-cells.
13 cl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| ANTIBODIES AGAINST TRANSFERRIN RECEPTOR HAVING INDIVIDUALIZED AFFINITY | 2016 |
|
RU2729416C2 |
| BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
| PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| BISPECIFIC ANTIBODIES TO HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR AND METHODS FOR THEIR USE | 2016 |
|
RU2753390C1 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
